Works matching IS 13419625 AND DT 2021 AND VI 26 AND IP 4


Results: 18
    1
    2
    3

    Detection of programmed cell death-ligand 1 using 22C3 antibody in patients with unresectable stage III non-small cell lung cancer receiving chemoradiotherapy.

    Published in:
    International Journal of Clinical Oncology, 2021, v. 26, n. 4, p. 659, doi. 10.1007/s10147-020-01856-x
    By:
    • Mamesaya, Nobuaki;
    • Muramatsu, Koji;
    • Yabe, Michitoshi;
    • Kodama, Hiroaki;
    • Nishioka, Naoya;
    • Miyawaki, Taichi;
    • Miyawaki, Eriko;
    • Kobayashi, Haruki;
    • Omori, Shota;
    • Wakuda, Kazushige;
    • Ono, Akira;
    • Kenmotsu, Hirotsugu;
    • Naito, Tateaki;
    • Murakami, Haruyasu;
    • Harada, Hideyuki;
    • Sugino, Takashi;
    • Shimizu, Tetsuo;
    • Gon, Yasuhiro;
    • Takahashi, Toshiaki
    Publication type:
    Article
    4
    5
    6
    7
    8
    9

    Real-world safety and effectiveness of radium-223 in Japanese patients with castration-resistant prostate cancer (CRPC) and bone metastasis: exploratory analysis, based on the results of post-marketing surveillance, according to prior chemotherapy status and in patients without concomitant use of second-generation androgen-receptor axis-targeted agents

    Published in:
    International Journal of Clinical Oncology, 2021, v. 26, n. 4, p. 753, doi. 10.1007/s10147-020-01850-3
    By:
    • Uemura, Hirotsugu;
    • Masumori, Naoya;
    • Takahashi, Shunji;
    • Hosono, Makoto;
    • Kinuya, Seigo;
    • Sunaya, Toshiyuki;
    • Horio, Tomoyo;
    • Okayama, Yutaka;
    • Kakehi, Yoshiyuki
    Publication type:
    Article
    10
    11

    Prognostic outcomes and risk factors for recurrence after laser vaporization for cervical intraepithelial neoplasia: a single-center retrospective study.

    Published in:
    International Journal of Clinical Oncology, 2021, v. 26, n. 4, p. 770, doi. 10.1007/s10147-020-01848-x
    By:
    • Kodama, Keisuke;
    • Yahata, Hideaki;
    • Okugawa, Kaoru;
    • Tomonobe, Hiroshi;
    • Yasutake, Nobuko;
    • Yoshida, Sachiko;
    • Yagi, Hiroshi;
    • Yasunaga, Masafumi;
    • Ohgami, Tatsuhiro;
    • Onoyama, Ichiro;
    • Asanoma, Kazuo;
    • Hori, Emiko;
    • Shimokawa, Mototsugu;
    • Kato, Kiyoko
    Publication type:
    Article
    12
    13
    14
    15

    Grade group 2 (10% ≥ GP4) patients have very similar malignant potential with grade group 1 patients, given the risk of intraductal carcinoma of the prostate.

    Published in:
    International Journal of Clinical Oncology, 2021, v. 26, n. 4, p. 764, doi. 10.1007/s10147-020-01841-4
    By:
    • Kato, Masashi;
    • Hirakawa, Akihiro;
    • Sato, Hiroyuki;
    • Hanazawa, Ryoichi;
    • Naito, Yushi;
    • Tochigi, Kosuke;
    • Sano, Tomoyasu;
    • Ishida, Shohei;
    • Funahashi, Yasuhito;
    • Fujita, Takashi;
    • Matsukawa, Yoshihisa;
    • Hattori, Ryohei;
    • Tsuzuki, Toyonori
    Publication type:
    Article
    16
    17
    18

    General rules for clinical and pathological studies on oral cancer (2nd edition): a synopsis.

    Published in:
    International Journal of Clinical Oncology, 2021, v. 26, n. 4, p. 623, doi. 10.1007/s10147-020-01812-9
    By:
    • Ota, Yoshihide;
    • Noguchi, Tadahide;
    • Ariji, Eiichiro;
    • Fushimi, Chihiro;
    • Fuwa, Nobukazu;
    • Harada, Hiroyuki;
    • Hayashi, Takafumi;
    • Hayashi, Ryuichi;
    • Honma, Yoshitaka;
    • Miura, Masahiko;
    • Mori, Taisuke;
    • Nagatsuka, Hitoshi;
    • Okura, Masaya;
    • Ueda, Michihiro;
    • Uzawa, Narikazu;
    • Yagihara, Kazuhiro;
    • Yagishita, Hisao;
    • Yamashiro, Masashi;
    • Yanamoto, Souichi;
    • Kirita, Tadaaki
    Publication type:
    Article